What is the current NervGen Pharma Corporation share price?

The current share price of NervGen Pharma Corporation is US$ 2.1201

How many NervGen Pharma Corporation shares are in issue?

NervGen Pharma Corporation has 106,203,136 shares in issue

What is the market cap of NervGen Pharma Corporation?

The market capitalisation of NervGen Pharma Corporation is USD 225.16M

What is the 1 year trading range for NervGen Pharma Corporation share price?

NervGen Pharma Corporation has traded in the range of US$ 0.05 to US$ 5.97 during the past year

What is the PE ratio of NervGen Pharma Corporation?

The price to earnings ratio of NervGen Pharma Corporation is -4.19

What is the registered address of NervGen Pharma Corporation?

The registered address for NervGen Pharma Corporation is 112-970 Burrard Street, Vancouver, British Columbia, V6Z 2R4

What is the NervGen Pharma Corporation website address?

The website address for NervGen Pharma Corporation is nervgen.com

Which industry sector does NervGen Pharma Corporation operate in?

NervGen Pharma Corporation operates in the Biotechnology & Life Sciences sector

NervGen Pharma【NGEN】銘柄情報

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0.1101	5.4776119403	2.01	2.16	1.85	865032	1.96595099	CS
4	0.1901	9.84974093264	1.93	2.345	1.7	874865	1.98198567	CS
12	-2.0499	-49.1582733813	4.17	4.35	1.7	809299	2.25370835	CS
26	2.0701	4140.2	0.05	5.97	0.05	455972	2.60016132	CS
52	2.0701	4140.2	0.05	5.97	0.05	225261	2.60016132	CS
156	2.0701	4140.2	0.05	5.97	0.05	75387	2.60016132	CS
260	2.0701	4140.2	0.05	5.97	0.05	45124	2.60016132	CS

期間 †

前日比

前日比 %

始値

高値

安値

平均出来高

VWAP

0.1101

5.4776119403

2.01

2.16

1.85

865032

1.96595099

0.1901

9.84974093264

1.93

2.345

1.7

874865

1.98198567

-2.0499

-49.1582733813

4.17

4.35

1.7

809299

2.25370835

2.0701

4140.2

0.05

5.97

0.05

455972

2.60016132

2.0701

4140.2

0.05

5.97

0.05

225261

2.60016132

156

2.0701

4140.2

0.05

5.97

0.05

75387

2.60016132

260

2.0701

4140.2

0.05

5.97

0.05

45124

2.60016132

NervGen Pharma: I Think The Biggest Risks Are Now Behind It
Jul 02, 2026, 12:25 PM ETNervGen Pharma Corp. (NGEN) StockXBI

Grassroots Trading

Summary
• NervGen Pharma remains a Buy, with reduced regulatory, financing, and execution risks following FDA alignment on the Phase 3 RESTORE trial.
• NGEN's recent $60M capital raise secures funding for its pivotal trial, shifting focus to NVG-291’s ability to replicate efficacy in chronic tetraplegia.
• Objective biomechanical gait analysis showed statistically significant improvements, reinforcing the case for NVG-291’s neural recovery over compensatory adaptation.
• With a risk-adjusted equity value of $7.50–$8.50 per share, NGEN offers significant upside if Phase 3 results mirror prior CONNECT SCI data.

Thesis
This marks the third time I'm covering NervGen Pharma (NGEN), a clinical-stage biotechnology company developing regenerative treatments for spinal cord injury. To date, I've been bullish on this high-risk stock because NVG-291 could become the first approved treatment to help patients with chronic tetraplegia regain meaningful function. NervGen is not as undervalued as it was a few months ago, but given the lower regulatory, financing, and execution risks, I still believe the stock is a good buy based on the potential upside if its clinical trials succeed.
From Scientific Promise to Clinical Execution
In my last coverage of NervGen, NVG-291’s evidence was the main point of discussion for NervGen shareholders. This is no longer the case. The focus is now more on execution. The science still needs to be tested in a registrational trial. However, most of the uncertainties outside of Phase 3 have been materially reduced.
A major milestone was the company’s successful End-of-Phase 2 meeting with the FDA, which resulted in consensus on the design of the RESTORE registrational study. Instead of carrying uncertainties around endpoints, dosing, and study design as it moves into late-stage development, NervGen now has FDA alignment on the design of a randomized Phase 3 trial enrolling approximately 150 patients with chronic tetraplegia. Management stated that CONNECT SCI data directly informed endpoint selection and trial design. Considering where the company was a few months ago, these developments significantly reduced regulatory uncertainty.
And NervGen appears more mature operationally.
In Q1, NervGen added leadership in finance, regulatory affairs, and patient advocacy to its executive team. This coincided with NervGen’s Nasdaq transition and preparation of RESTORE clinical sites. CEO Adam Rogers noted the company is “firmly in execution mode.” From my angle, this seems justified since site activation is already underway and NervGen is on target to start Phase 3.
Management has also tackled what is probably the most significant practical shareholder issue: funding.
The public offering in May raised approximately $60 million to fund the registrational program and removed the biggest near-term concern. Naturally, shareholders would prefer zero dilution, but that was always on the table. Besides, financing risk is different from clinical risk. The point is, I and other shareholders included are no longer wondering if NervGen has the funding to start Phase 3. Instead, the discussion has narrowed to if NVG-291 can reproduce the same results in the pivotal study.
Better Data, Better Commercial Odds
What changed in the past few months was the type of evidence produced by NervGen. One of the biggest challenges in spinal cord injury research has been telling the difference between real recovery of the nervous system and the body's ability to compensate by finding other ways to perform the same movement or function. That is, neuropathically injured patients sometimes perform learned movements without repairing the damaged neural pathways. The distinction of the two processes makes a major difference here because regulators and physicians and, thereafter, payers need the confidence that the development of any functional improvement will not be an adaptive response.
So, I think the company’s independent, blinded biomechanical gait analysis deserved more attention. Rather than focusing only on conventional clinical tests, the analysis measured how well people coordinated their movements, how much physical effort it took to walk, and how well they maintained balance and posture. It used objective motion capture and a Global Statistical Test to evaluate these measurements.
Patients who received NVG-291 showed statistically significant improvement on the composite assessment (p=0.0197). All patients administered NVG-291 were classified as responders, compared with only one patient in the placebo group, and NVG-291 patients showed improvements in walking speed without an increase in mechanical effort. This circles back to my previous point that this likely demonstrates that the improvement in walking speed was the result of better neural control and not secondary compensation due to the injury. These results also support earlier documented improvements in electrophysiological signaling, upper-limb function, independence, and quality of life, which provide a much more consistent efficacy package than investors had a few months ago.
Wall Street also appears to be responding more seriously to that evidence as well.
Last month, TD Cowen began coverage of the stock with a Buy rating after speaking with some key opinion leaders and walked away with an opinion that a successful launch might support peak annual sales of $1.1 billion. Generally speaking, I try not to put too much stock in the opinion of one analyst. Still, the report does stand out to me because it suggests institutional analysts are starting to view NervGen less like an early-stage science project and more like a company with a clear commercial opportunity. Of course, that doesn't make the upcoming Phase 3 trial any less risky.
Another thing that's working in NervGen's favor doesn't have to do specifically with NVG-291. The current setting in comparison to last year for development-stage biotech is much better. For instance, capital is returning to biotech.

Seeking Alpha
Over the past year, the SPDR S&P Biotech ETF (XBI) experienced nearly $1.3 billion in net inflows and almost a doubling since the 2025 lows. At the same time, acquisitions have picked up as large pharmaceutical companies continue looking for new drugs and technologies to add to their pipelines before major patents on their existing products expire.
Perhaps even more importantly for companies like NervGen, investors seem to be placing more value on companies that are close to pivotal clinical trials and have clinical data that clearly set them apart from competitors. I believe NervGen’s fit to the market is much stronger now than it was a couple of years ago. If NervGen was at this point during the biotech downturn, raising enough capital to launch a registrational trial likely would have come at a much steeper cost to shareholders.
Risk And Valuation

Seeking Alpha
Keep in mind, valuing NGEN has always been a high-risk proposition since the company has no revenue, no earnings, and generated an operating cash outflow of roughly $16.9 million over the trailing twelve months.
Relatively traditional metrics such as P/E, EV/Sales, and price-to-book would be of little use here. Instead, I continue to rely on a risk-adjusted framework built around the commercial potential of NVG-291.
I've changed three assumptions as compared to my previous models. First, I believe the probability of success has increased after the FDA’s alignment on Phase 3 of the RESTORE study, in addition to the other independent biomechanical data. Second, the May financing dealt with a near-term funding risk.

Seeking Alpha
Even so, we know that it came with a cost: shares increased to roughly 81 million. Finally, there has been a positive change in how the commercial opportunity is being viewed. While my previous model assumed peak annual sales of about $700 million, I can now increase that estimate significantly based on Wall Street's projection that NVG-291 could generate approximately $1.1 billion in peak annual sales if it reaches the market.
Factoring in a more moderate peak sales estimate of approximately $900 million, a conservative 5× peak sales multiple typical of orphan and specialty biotech companies, a 50% probability of approval, and a 12% discount rate applied to peak commercialization value, I estimate an equity value of approximately $600–700 million, or roughly $7.50–$8.50 per share using approximately 81 million shares outstanding. That represents significant potential upside from the current price, and the recent share price decline has improved the risk-reward profile, especially since NervGen’s regulatory, financing, and commercial outlook has strengthened since my last coverage.
Rating: Buy
The biggest unknown is Phase 3. I think the stock is still undervalued if the RESTORE trial backs up what was seen in the CONNECT SCI trial. Especially the functional improvements with supporting objective biomechanical evidence. If the RESTORE trial doesn’t deliver, well, then all that value disappears. This has always been a high-risk, all-or-nothing situation for the very small portion of my portfolio, maybe yours too, that justifies its place, but I don’t see the deep mispricing to support that more aggressive approach as strongly as before.